In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …
Endometriosis affects a substantial proportion of women of reproductive age and is a common, often under-recognised contributor to subfertility. Its effects on fertility are multifactorial, and both the disease and …
Endometriosis presents a multitude of challenges for individuals. Current treatment of the disease is based on pharmacotherapy that aims to relieve pain, improves future fertility, potentially slows disease progression and …
To evaluate the efficacy of oral gonadotropin-releasing hormone (GnRH) antagonists versus placebo for treatment of endometriosis-associated pain and to compare individual antagonists indirectly for dysmenorrhea and non-menstrual pelvic pain.
Elagolix, Linzagolix, and Relugolix, as oral gonadotropin-releasing hormone antagonists, have emerged as promising treatments for endometriosis-associated pain.
Background: The management of endometriosis-associated pain has traditionally focused on analgesic efficacy. However, with high-level evidence demonstrating therapeutic equivalence among principal hormonal classes, the paradigm has shifted towards a patient-centred …
Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …